Autres langues EirGenix Inc.

Actions

6589

TW0006589005

Cours en clôture Taipei Exchange Autres places de cotation 00:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
80,7 ^TWD	-1,10 %		+2,54 %	-19,70 %

22/03	EirGenix Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
08/03	EirGenix, Inc. décide de signer le contrat avec l'ORC clinique et les entreprises concernées pour la phase III de l'essai clinique du EG1206A	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	08/03
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	23/11
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	09/11
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	18/09/23
Novartis-Krebsmedikament Trastuzumab erhält EMA-Empfehlung	18/09/23
Novartis Cancer Drug Gets Marketing Recommendation from European Medicines Agency	18/09/23
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	18/09/23
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	18/09/23
Sandoz erhält positive CHMP-Stellungnahme für Krebs-Biosimilar	18/09/23
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	03/05/23
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23
EirGenix Inc. announced a financing transaction	10/03/23
EirGenix Inc. Announces Executive Changes	10/01/23
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	28/12/22
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22
Eirgenix, Inc., Submits the Biosimilar Drug Eirgasum of 150 Mg Powder for Concentratefor Solution for Infusion Presentation New Drug Application to the Taiwan Food and Drug Administration	30/09/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues EirGenix Inc.

Actions

6589

TW0006589005

Autres langues

Filtres